Cannabinoid Receptors Modulate Neuronal Morphology and AnkyrinG Density at the Axon Initial Segment by Garrido Jurado, Juan José
ORIGINAL RESEARCH
published: 25 January 2017
doi: 10.3389/fncel.2017.00005
Cannabinoid Receptors Modulate
Neuronal Morphology and AnkyrinG
Density at the Axon Initial Segment
Mónica Tapia 1* †, Ana Dominguez 1, Wei Zhang 1, Ana del Puerto 1, María Ciorraga 1,
María José Benitez 1,2, Carmen Guaza 1 and Juan José Garrido 1*
1 Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain, 2 Department of Quimica Fisica
Aplicada,Universidad Autónoma de Madrid, Madrid, Spain
Edited by:
Vann Bennett,
Howard Hughes Medical Institute,
USA
Reviewed by:
Maarten H. P. Kole,
Netherlands Institute for
Neuroscience (KNAW), Netherlands
Matthew S. Grubb,
King’s College London, UK
Christian Schultz,
Heidelberg University, Germany
*Correspondence:
Mónica Tapia
monica.tapia-pacheco@univ-amu.fr
Juan José Garrido
jjgarrido@cajal.csic.es
†Present address:
Mónica Tapia,
Faculté de Médecine Secteur Nord,
Inserm UMR 1072, Aix Marseille
University, Boulevard Pierre Dramard,
Marseille, France
Received: 20 September 2016
Accepted: 10 January 2017
Published: 25 January 2017
Citation:
Tapia M, Dominguez A, Zhang W, del
Puerto A, Ciorraga M, Benitez MJ,
Guaza C and Garrido JJ
(2017) Cannabinoid Receptors
Modulate Neuronal Morphology and
AnkyrinG Density at the Axon Initial
Segment.
Front. Cell. Neurosci. 11:5.
doi: 10.3389/fncel.2017.00005
Neuronal polarization underlies the ability of neurons to integrate and transmit
information. This process begins early in development with axon outgrowth, followed
by dendritic growth and subsequent maturation. In between these two steps, the
axon initial segment (AIS), a subcellular domain crucial for generating action potentials
(APs) and maintaining the morphological and functional polarization, starts to develop.
However, the cellular/molecular mechanisms and receptors involved in AIS initial
development and maturation are mostly unknown. In this study, we have focused
on the role of the type-1 cannabinoid receptor (CB1R), a highly abundant G-protein
coupled receptor (GPCR) in the nervous system largely involved in different phases
of neuronal development and differentiation. Although CB1R activity modulation has
been related to changes in axons or dendrites, its possible role as a modulator of
AIS development has not been yet explored. Here we analyzed the potential role of
CB1R on neuronal morphology and AIS development using pharmacological and RNA
interference approaches in cultured hippocampal neurons. CB1R inhibition, at a very
early developmental stage, has no effect on axonal growth, yet CB1R activation can
promote it. By contrast, subsequent dendritic growth is impaired by CB1R inhibition,
which also reduces ankyrinG density at the AIS. Moreover, our data show a significant
correlation between early dendritic growth and ankyrinG density. However, CB1R
inhibition in later developmental stages after dendrites are formed only reduces ankyrinG
accumulation at the AIS. In conclusion, our data suggest that neuronal CB1R basal
activity plays a role in initial development of dendrites and indirectly in AIS proteins
accumulation. Based on the lack of CB1R expression at the AIS, we hypothesize that
CB1R mediated modulation of dendritic arbor size during early development indirectly
determines the accumulation of ankyrinG and AIS development. Further studies will
be necessary to determine which CB1R-dependent mechanisms can coordinate these
two domains, and what may be the impact of these early developmental changes once
neurons mature and are embedded in a functional brain network.
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INTRODUCTION
The establishment of a functional brain network depends on the
ability of neurons to reach and activate their specific targets via
the growth and elongation of their axons. Axonal outgrowth is
the first morphological event of neuronal polarization, followed
by the development of dendrites and axon initial segment
(AIS) formation (Ramón Y Cajal, 1897; Kaech and Banker,
2006). The AIS plays an essential role in maintaining neuronal
polarity and axon integrity and identity (Hedstrom et al., 2008).
Functionally, the AIS is a unique neuronal domain comprising
high densities of Na+, K+ and Ca2+ voltage-gated ion channels
(for a review see Bender and Trussell, 2012). These voltage-
gated ion channels are anchored in the AIS by interactions
with scaffold cytoskeletal proteins, such as ankyrinG or PSD-93
(Garrido et al., 2003; Pan et al., 2006; Ogawa et al., 2008).
Among other factors, the high density of ion channels confers
on the AIS the property of being the site of action potential
(AP) initiation (Stuart et al., 1997; Kole et al., 2008). In fact,
the AIS acts as an electrical gatekeeper, becoming the decision
point for initiation of APs. The AIS performs this function by
summing all excitatory and inhibitory inputs from thousands
of synapses until a critical firing threshold is reached and the
AP is irreversibly triggered. The scaffold protein ankyrinG is
the AIS master regulator and is necessary for its assembly and
maintenance, such that ankyrinG suppression leads to a loss
of axonal identity characterized by the appearance of dendritic
spines in former axonal structures (Hedstrom et al., 2008;
Sobotzik et al., 2009). Over the past 20 years, many studies have
contributed to describe AIS molecular structure, function and
some regulatory mechanisms (some examples and reviews are:
Kobayashi et al., 1992; Zhou et al., 1998; Garrido et al., 2003;
Rasband, 2010; Grubb et al., 2011; Sanchez-Ponce et al., 2011;
Bender and Trussell, 2012; Zollinger et al., 2015; Huang and
Rasband, 2016). Furthermore, the discovery of AIS structural
plasticity (changes in position or length) and its capacity to adapt
in response to different physiological and pathological conditions
in order to maintain neuronal survival and excitability shed
light on the dynamical complexity of the AIS (Schafer et al.,
2009; Grubb and Burrone, 2010; Kuba et al., 2010). Besides AIS
structural plasticity, AIS proteins density also can change in
response to physiological or pathological stimuli (Kuba et al.,
2015; del Puerto et al., 2015).
However, it is now important to understand which neuronal
or glial mechanisms, and which membrane receptors, contribute
to different types of AIS modulation. Moreover, the mechanisms
involved in the targeting and modulation of AIS proteins during
the very early stages of neuronal development remain elusive.
Recent studies have shown that the purinergic system (del Puerto
et al., 2015), serotonin receptors (Ko et al., 2016) or GABAergic
innervation (Muir and Kittler, 2014) influence and modulate AIS
proteins and neuronal excitability. However, the role of another
important neuromodulatory system, the cannabinoid system,
has not been analyzed in the context of AIS development and
maturation.
The endocannabinoid system (ECS) comprises
endocannabinoids (eCB) such as 2-arachidonoyl glycerol (2-AG)
and n-arachidonoyl ethanolamine (AEA or anandamide),
the enzymes responsible for their synthesis/degradation and
the cannabinoid receptors. Among cannabinoid receptors,
type-1 cannabinoid receptor (CB1R) is abundantly expressed
in the central nervous system, particularly in the cortex, basal
ganglia, hippocampus and cerebellum (Mackie, 2005), and
is considered one of the most abundant G protein-coupled
receptors (GPCRs) expressed in the brain (Matsuda et al.,
1990; Kano et al., 2009). CB1R coupling to Gi/o proteins leads
to multiple downstream events depending on the cell type:
adenylyl cyclase inhibition, voltage-gated calcium channel
inhibition, activation of inwardly rectifying potassium channels
and activation of mitogen-activated protein kinases (Howlett,
2005). Despite the lack of highly specific pharmacology for the
study of cannabinoid receptors, several studies have suggested
that CB1Rs are mostly present in axon terminals, and also
in astrocytes (Navarrete and Araque, 2010), and control a
wide spectrum of physiological and pathological conditions
(Katona and Freund, 2012; Mechoulam and Parker, 2013).
The type-2 cannabinoid receptors (CB2Rs) are considered
the predominant cannabinoid receptor in the immune system
and their neuronal expression has only been described under
certain pathological conditions (Viscomi et al., 2009). Besides
their well-known functions as neuromodulators, controlling
both neuronal excitability and synaptic plasticity at different
scales (Chevaleyre et al., 2006; Kano et al., 2009; Marinelli
et al., 2009; Katona and Freund, 2012), eCB also seem to be
involved in brain development and axonal pathfinding (Mulder
et al., 2008; Keimpema et al., 2011). Indeed, CB1Rs are highly
expressed in the developing brain (Vitalis et al., 2008), and
axon development and pathfinding are disrupted during pre-
and post natal brain development in CB1R knock out mice
(Mulder et al., 2008; Wu et al., 2010). CB1Rs are also involved
in the regulation of adult neurogenesis, such that their loss
inhibits neuronal progenitor cell proliferation in vivo and
in vitro. Moreover CB1R expression in neural progenitors
increases along neuronal differentiation, allowing eCBs to
control neuronal specification and morphogenesis (reviewed in
Galve-Roperh et al., 2013).
Thus, a tempting idea is that cannabinoid receptors play
an important role during the early stages of neuronal domain
development and maturation. In this article, we will focus on
new data concerning the role of the cannabinoid system in the
modulation of AIS and its relation with axonal and dendritic
development. We demonstrate a differential neuronal CB1R
modulation of axonal and dendritic development, as well as a
role of CB1R on the modulation of ankyrinG density at the
AIS at different early developmental stages. Moreover, our data
suggest that glial CB2Rs also participate in ankyrinG density
maintenance.
MATERIALS AND METHODS
Reagents and Plasmids
2-AG, AM-251, AM630 and SR141716A were obtained from
Tocris. UCM-03025 was a gift from María Luz Lopez Rodriguez
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laboratory (Complutense University, Madrid; Hernández-Torres
et al., 2014). CB1R interference RNA and scrambled RNA
plasmids (Origene) were a kind gift of Dr. Ismael Galve-
Ropert (Universidad Complutense, Madrid) and were previously
validated (Diaz-Alonso et al., 2012).
Animals
Animals were housed in a room at controlled temperature and
relative humidity with alternating 12 h light and dark cycles and
free access to food and water ‘‘ad libitum’’. Animal care protocols
used in our laboratory are in conformity with the appropriate
national legislation (53/2013, BOE no. 1337) and guidelines
of the Council of the European Communities (2010/63/UE).
All protocols were previously approved by the CSIC bioethics
committee.
Neuronal Culture
Mouse hippocampal neurons were prepared as previously
described (del Puerto et al., 2012, 2015). Neurons were obtained
from E17 mouse hippocampi, which were incubated in a
0.25% trypsin solution in Ca2+/Mg2+ free Hank’s buffered salt
solution (HBSS) and dissociated using fire-polished Pasteur
pipettes. The cells were plated on polylysine-coated coverslips
(1 mg/mL) at a density of 5000 cells/cm2 for 2 h in plating
medium (minimum essential medium [MEM], 10% horse serum,
0.6% glucose, Glutamax-I and antibiotics). Then coverslips
were inverted and transferred to culture dishes containing
astrocytes. Astrocyte medium was replaced by neuronal culture
medium 24 h before neuronal culture (Neurobasal medium,
B27 supplement, Glutamax-I). To avoid contact between neurons
and astrocytes, paraffin beads were placed on coverslips before
neuronal plating. 5 µM 1-β-D-arabinofuranosylcytosine (AraC)
was added after 2 days in culture to avoid glial proliferation.
Pharmacological treatments were applied as described in the
‘‘Results’’ Section. In the case of pharmacological treatments in
the absence of glial cell layer, coverslips were transferred to plates
containing glial cell-conditioned medium. Primary hippocampal
neurons were nucleofected using the Amaxa nucleofector
kit for primary mammalian neural cells (Amaxa Bioscience)
according to the manufacturer’s instructions. Nucleofection
was performed using 3 µg of total DNA and 3 × 106 cells
for each nucleofection. Neurons were plated at a density of
10,000 cells/cm2 as described above. Nucleofection efficiency was
∼15% of neurons, based on the number of GFP-positive neurons.
For Western-blot experiments, neurons were plated at a density
of 50,000 cells/cm2 and processed as previously described (Tapia
et al., 2013).
Immunofluorescence
Neurons were fixed in 4% PFA, then coverslips were treated
for 10 min with 50 mM NH4Cl and incubated in blocking
buffer (0.22% gelatin, 0.1% Triton X-100 in PBS) for 30 min,
before incubation with primary antibodies for 1 h at room
temperature in blocking buffer. For CB1R staining, neurons
were incubated for 30 min at 37◦C with anti-CB1R antibody,
then rinsed three times and fixed to continue the procedure
with other antibody staining. The primary antibodies used were:
chicken anti-MAP2 (1:10,000, Abcam), mouse anti-ankyrinG
(1:100) from NeuroMab, anti-Tau-1 from Millipore (1:1000)
and rabbit anti-CB1R (1:50) from Cayman (Cat. 101500).
The secondary antibodies used were a donkey anti-mouse,
anti-rabbit or anti-chicken Alexa-Fluor 488, 594, or 647 (1:1000).
Phalloidin Alexa-Fluor 594 was used at a concentration of
1:100. Nuclei were stained using 4′,6-diamidino-2-phenylindole,
and coverslips were mounted in Fluoromount G. Images were
acquired on a vertical Axioskop-2 plus microscope (Zeiss) or
a Leica SP5 confocal microscope under the same conditions
to compare intensities. Figures were prepared for presentation
using the Adobe CS4 software.
Dendrites, Axon and AIS Measurements
Quantification of fluorescence intensity at the AIS was performed
in neurons from at least three independent experiments.
Measurements of ankyrinG fluorescence intensity were
performed on confocal images. Using ImageJ software we
drew a line starting at the limit of neuronal soma identified by
MAP2 staining, and extended it along the ankyrinG staining
or the GFP signal of the axon. Data from every 0.16 µm
along the first 40 µm were obtained and smoothed using the
Sigmaplot software to obtain average ankyrinG fluorescence
intensity every 1 µm. Data were normalized in each neuron
considering the value of maximum mean fluorescence in control
neurons to be 100%. Total fluorescence intensity for each neuron
was obtained by adding ankyrinG fluorescence values from
0 µm to 40 µm. AIS start, end and maximum fluorescence
intensity were determined following the criteria described in
Grubb and Burrone (2010). Taking 100% fluorescence as the
maximum fluorescence intensity point, start and end points
were defined as the points were fluorescence intensity is lower
than 33%.
Dendrite and axon lengths were obtained based on MAP2 or
Tau-1 staining using NeuronJ software to measure the length of
dendritic arbor in each neuron or the axonal length including
ramifications. In order to study correlations between dendrites
and AIS fluorescence, both data were obtained from the same
neurons.
Statistical Analysis
All statistical analyses were carried out in Sigmaplot v12.5
(Systat Software Inc., San Jose, CA, USA) and Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA). Data for
each independent sample were obtained from at least three
independent experiments. Data from each experiment were
collected from at least 30 cells (between 30 and 50 cells)
in each experimental condition. Statistical analysis was
performed by t-test for two group comparisons and one-way
ANOVA for multiple group comparisons. When data were
non-normally distributed, non-parametric tests were used:
Mann-Whitney Rank test for two independent samples and
Kruskal-Wallis for analysis of multiple groups. In the analysis
of multiple comparison, a post hoc analysis was performed
using Bonferroni’s (in the case of ANOVA) or Dunn’s test
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(in the case of Kruskal-Wallis). All p-values were adjusted
to account for multiple comparison. Cell-to-cell analysis of
dendrite length and ankyrinG fluorescence was performed
using Prism 6 and Sigmaplot v12.5 with a Pearson product
moment test. Differences were considered significant when
p< 0.05.
RESULTS
CB1Rs Modulate Axonal and Dendritic
Development
In order to understand how cannabinoids may modulate
neuronal development, we studied their role during axonal
growth and dendrite development. First, we analyzed the
expression of CB1R in cultured hippocampal neurons using
a polyclonal antibody directed against the N-terminus of
the receptor (Howlett et al., 1998). CB1R was detected
by Western-blot after 2 days in vitro (2 DIV) and its
expression progressively and markedly increased until 13 DIV
(Figure 1A). Next, we analyzed its membrane subcellular
localization by immunocytochemistry at different developmental
stages. Consistent with previous reports (Irving et al., 2000),
the analysis of receptor immunoreactivity revealed a punctate
pattern along the axon and at the growth cone in 2-DIV
neurons (Figure 1B). While the same pattern of staining was
conserved in older neurons (6 DIV), no CB1R expression was
detected in dendrites or in the AIS (Figure 1C). Based on
this specific pattern of subcellular localization of CB1R, we
sought to determine whether CB1R could be involved in axonal
elongation. Hippocampal neurons were cultured since plating
until 2 DIV in the presence of 2-AG (3 µM) alone or in
combination with the CB1R antagonists AM251 (3 µM) or
SR141716A (1 µM; Figure 1D). Axon length was increased
by 40% in neurons treated with only 2-AG (408.03 ± 19.92
µm compared to 288.12 ± 12.97 µm in non-treated control
neurons, Kruskal-Wallis, Dunn’s multiple comparison test,
p < 0.0001, Figure 1E). However, treatment of neurons with
two different CB1 antagonists had no effect on axonal growth
(286.74 ± 13.07 µm for AM251 and 282.03 ± 19.52 µm
for SR141716A vs. 288.12 ± 12.97 µm in control neurons,
Kruskal-Wallis, Dunn’s multiple comparisons test, Figure 1E).
In order to demonstrate that axonal elongation following 2-AG
application was specifically due to CB1R activation, neurons were
pre-incubated for 1 h with the CB1R antagonists AM251 or
SR141716A before 2-AG application (Figure 1E). The addition
of CB1R antagonists prevented the 2-AG-mediated increase in
axonal elongation (273.21 ± 18.1 µm for 2-AG + AM251 and
283.28 ± 23.1 µm for 2-AG + SR141716A vs. 408.03 ± 19.92
µm in 2-AG treated neurons, p < 0.0001 and p < 0.05,
and 288.12 ± 12.97 µm in control neurons, Kruskal-Wallis,
Dunn’s multiple comparisons test, Figure 1E), confirming
that CB1R activation promotes axonal elongation. In addition,
2-AG treatment also increased axonal ramification and, as
observed for axonal elongation, this increase was prevented
when neurons were pre-incubated for 1 h with the CB1R
antagonists (Figure 1F). Moreover, we tested the effect of
increasing endogenous levels of 2-AG by using UCM-03025,
a monoacylglycerol lipase (MAGL) inhibitor that prevents
2-AG degradation (Hernández-Torres et al., 2014). Similar to
what occurred when neurons were treated with 2-AG, MAGL
inhibition also promoted axonal elongation (467.54 ± 25.35 µm
for UCM 1 µM vs. 324.15 ± 14.42 µm in control neurons,
Kruskal-Wallis, Dunn’s multiple comparisons test, p < 0.0001,
Figure 1G).
Our results are in agreement with the increased density of
axonal markers observed during the development of zebrafish
treated with the CB1 agonist WIN55212-2 (Gilbert and
Soderstrom, 2014). However, while these authors showed an
increased density of dendritic proteins after CB1R activation
during development (but not in adult), we did not detect CB1R
expression in dendrites. In this regard, while somatodendritic
CB1R visualization is difficult using immunocytochemical
and/or immunohistochemical approaches, new evidence of
functional CB1Rs in postsynaptic dendritic domains have been
provided by electrophysiological (Bacci et al., 2004; Marinelli
et al., 2009) and live imaging studies (Leterrier et al., 2006;
Ladarre et al., 2015). To test whether CB1R had an effect
on dendritic development, hippocampal neurons were cultured
until 6 DIV and treated at 0, 2 and 4 DIV with 2-AG or
CB1R antagonists alone or combined (Figure 2A). Unlike what
was observed for axonal growth, neither 2-AG nor UCM-03025
treatments did significantly modify the total dendritic length
(433.18 ± 22.75 µm for 2-AG and 524.8 ± 34.28 µm for UCM
µm vs. 422.06 ± 20.25 µm in control neurons, Kruskal-Wallis,
Dunn’s multiple comparisons test, Figure 2B). However, when
neurons were treated with CB1R antagonists, total dendritic
length was reduced to less than 50% of the control value
(204.18 ± 14.06 µm for AM251 and 191.07 ± 16.56 µm
for SR1141716A vs. 422.06 ± 20.25 µm in control neurons,
Kruskal-Wallis, Dunn’s multiple comparisons test, p < 0.0001
Figure 2B). The same result was obtained when antagonists
were applied in combination with 2-AG. Altogether, these data
suggest a differential modulation of somatodendritic and axonal
morphologies by CB1Rs: CB1R basal activity seems necessary
for adequate dendrite development, while axon growth does not
require CB1R activity, although application of exogenous 2-AG
can potentiate axon growth.
Cannabinoid Receptors and Axon Initial
Segment Development
Since theoretical mathematical models have shown that dendritic
size and/or morphology influence AP onset and AIS plasticity
(Eyal et al., 2014; Gulledge and Bravo, 2016), we hypothesized
that the basal CB1R activity related to dendritic development
described here could also influence AIS development. Thus,
we investigated whether CB1R had an effect on AIS formation
and maturation. For that purpose we analyzed the density of
one of the main proteins of the AIS, ankyrinG, in different
experimental conditions modulating both the activity and
the expression of CB1Rs. First, we analyzed the possible
role of CB1R on the formation and initial development
of the AIS. We treated hippocampal neurons every other
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FIGURE 1 | Modulation of axonal growth by the type-1 cannabinoid receptor (CB1R). (A) Western-blot showing CB1 receptor total expression levels on 2, 3,
7 and 13-days in vitro (DIV) hippocampal neurons. (B) CB1 receptor (green) expression in 2-DIV hippocampal neurons. Growth cones are stained with
phalloidin-Alexa 594 (red), axons with Tau-1 antibody (blue) and nuclei with DAPI (white). The inset shows a magnification of the growth cone region. Note that
CB1 receptors show a punctate staining and are mainly concentrated in the axonal growth cone and along the axonal shaft (image below). (C) CB1 receptor (green)
expression in 6-DIV hippocampal neurons. CB1 receptors are expressed along the axon and are not detected by immunofluorescence in the dendrites (red) or the
axon initial segment (AIS; blue). Magnification of the image is shown below with or without AIS marker staining (AnkyrinG, blue). (D) 2-DIV hippocampal neurons
treated with 2-Arachidonylglycerol (2-AG) or 2-AG in combination with AM251 from plating until 2 days. Neurons were stained using a Tau-1 antibody and Phalloidin
for better recognition of neuronal and axonal morphology. Scale bar = 100 µm. (E–G) Bar plots representing the mean ± SEM of axonal length or total number of
axonal ramifications of 2-DIV hippocampal neurons treated with CB1R antagonists, and/or agonist (E,F) or treated with monoacylglycerol lipase (MAGL) inhibitor
UCM03025 (G). Data were acquired from three independent experiments (30 neurons/experimental condition in each experiment). Kruskal-Wallis, Dunn’s multiple
comparisons test. Adjusted p values: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001; ns, non-significant.
day (0, 2 and 4 DIV) until 6 DIV with 2-AG and CB1R
antagonists alone or combined, as mentioned above for the
analysis of dendrites (Figures 3A,B). As shown for dendritic
development, 2-AG or UCM-03025 treatments did not modify
the ankyrinG fluorescence signal compared to control neurons
(100 ± 3.58% for control neurons vs. 98.93 ± 2.62% for 2-AG
and 92.87 ± 2.24% for UCM, ANOVA, Bonferroni multiple
comparisons test, Figure 3C). By contrast, CB1R inhibition with
Frontiers in Cellular Neuroscience | www.frontiersin.org 5 January 2017 | Volume 11 | Article 5
Tapia et al. Cannabinoid Modulation of the Axon Initial Segment
FIGURE 2 | CB1R activity is necessary for dendritic development. (A) 6-DIV hippocampal neurons treated with CB1R antagonists, and/or agonist or treated
with the MAGL inhibitor UCM03025. Drugs were first added after plating and treatment was repeated every other day. After 6 days in culture, neurons were stained
with MAP2 antibody to detect the somatodendritic domain and DAPI for nuclei. Scale bar = 100 µm. (B) Bar plots representing the mean ± SEM of total dendritic
length. Data were acquired from three independent experiments (30 neurons/experimental condition in each experiment). Kruskal-Wallis, Dunn’s multiple
comparisons test. Adjusted p values: ∗∗∗∗p < 0.0001; ns, non-significant.
AM251 or SR141716A alone or in combination with 2-AG
reduced the ankyrinG signal by ∼30% (70.39 ± 3.16% for
AM251, 69.73 ± 1.76% for SR141716A, 71.29 ± 4.97% for
AM251 + 2-AG and 70.48 ± 6.73% for SR141716A + 2-AG vs.
100 ± 3.58% in control neurons, ANOVA, Bonferroni multiple
comparisons test, p < 0.01 Figure 3C). These results clearly
suggest that CB1R activity modulates AIS formation during
early development in vitro, and that a basal CB1R activity is
necessary for initial dendritic formation and AIS accumulation
of ankyrinG.
We then wondered whether CB1R activity could also
participate in AIS maintenance and maturation at later stages
of development after dendritic maturation has started. Thus
we treated 7-DIV hippocampal neurons daily for 3 days, until
10 DIV, with 3 µM 2-AG or 3 µM AM251 (Figures 4A,B)
and then we analyzed the expression of ankyrinG along
the AIS (Figure 4C) and the total ankyrinG expression in
the AIS (Figure 4D). As had been observed for dendrites,
treatment with 2-AG did not significantly increase ankyrinG
intensity in the AIS (110.28 ± 3.17% vs. 100 ± 2.72% in
control neurons), whereas CB1 inhibition with AM251 decreased
ankyrinG intensity by ∼20% (82.94 ± 2.9%, Kruskal-Wallis,
Dunn’s multiple comparisons test, p < 0.0001, Figure 4E). No
change in AIS length or position was observed (Figure 4E).
However, the maximum fluorescence intensity position shifted
slightly and significantly by 2 µm towards the soma in
AM251-treated neurons compared to control neurons (Kruskal-
Wallis, Dunn’s multiple comparisons test, p < 0.05). In
addition, no apparent changes in dendritic arbor were observed
after 2-AG or AM251 treatments. Thus, while CB1R activity
modulates the initial development of dendrites, at least
in vitro, CB1R inhibition after 7 DIV does not affect
the growth of dendrites, and is only necessary for AIS
maturation.
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FIGURE 3 | CB1R inhibition decreases ankyrinG expression at the developing AIS. (A,B) 6-DIV hippocampal neurons treated with 2-AG or UCM-03025 (A),
or 2-AG in combination with AM251 (B). AIS domain stained for ankyrinG is included in a box and its magnification shown below (A) or in the right (B) for every
image. Drugs were first added after cell plating and treatment was repeated every other day. After 6 days in culture, neurons were fixed and stained for MAP2 (red) to
visualize somatodendritic compartment, and ankyrinG (AnkG, green) to visualize the AIS. All images were acquired using the same fluorescence parameters. Scale
bar = 100 µm. (C) Bar plots representing the mean ± SEM of normalized AnkyrinG total fluorescence intensity along the AIS. Data were acquired from three
independent experiments (30 neurons/experimental condition in each experiment). ANOVA, Bonferroni multiple comparisons test. Adjusted p values: ∗∗p < 0.01;
∗p < 0.05; ns, non-significant; a.u., arbitrary units.
One more point that needs to be considered is the fact
that CB1R expression and activity in astrocytes (Navarrete
and Araque, 2010) may be essential at these developmental
stages for proper control of neuronal excitability. Indeed, CB1R
activation in astrocytes can trigger the astrocytic release of
neurotransmitters onto neurons (Gómez-Gonzalo et al., 2015).
On the other hand, while CB2R expression in astrocytes and
neurons in physiological conditions is controversial (Stella,
2010), this receptor has a role in embryonic and neural
progenitors (Palazuelos et al., 2012). Thus, we tested whether
CB2R activation by 2-AG or any possible non-CB1 effect of
AM-251 on CB2R (Pertwee, 2005) could be responsible for
AIS changes. First, we cultured 7-DIV hippocampal neurons
for 3 days in the presence or absence of a layer of astroglial
cells (Figures 5A,B). In the absence of glial cells, neurons
were cultured in glial cell-conditioned medium. Neurons were
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FIGURE 4 | CB1R inhibition, after dendrites formation, diminishes ankyrinG expression at the AIS. (A,B) 10-DIV hippocampal neurons treated daily with
cannabinoid receptor agonist 2-AG or CB1R antagonist AM251 from 7 to 10 days. High-magnification pictures of the AIS of each neuron are shown in (B). Scale
bar = 100 µm. (C) AnkyrinG fluorescence intensity profile along the AIS in control, 2-AG- or AM251-treated neurons. Data were acquired from three independent
experiments (30 neurons/experimental condition in each experiment). (D) Normalized ankyrinG total fluorescence intensity at the AIS of neurons represented in (C).
(E) Graph representing the mean ± SEM of the start and end positions of the AIS, as well as, the position of the maximum fluorescence intensity at the AIS for each
experimental condition. Kruskal-Wallis, Dunn’s multiple comparisons test. Adjusted p values: ∗p < 0.05; ∗∗∗∗p < 0.0001, ns, non-significant; a.u., arbitrary units.
treated daily for 3 days with the CB2R antagonist AM630
(100 nM) and then we analyzed ankyrinG intensity along the AIS
(Figures 5C,D). Interestingly, the presence of a glial cell layer
reduced ankyrinG maximal intensity by 20% when CB2 receptor
was inhibited (83.55± 2.72% vs. 100± 2.75% in control neurons,
Mann-Whitney Rank test, p < 0.05, Figure 5E). However, no
change in ankyrinG intensity was detected in neurons treated
in the absence of glial cells (95.61 ± 2.16% vs. 100 ± 2.95% in
control neurons, Mann-Whitney Rank test, Figure 5E). Hence,
while a neuron-specific CB2R effect on AIS maturation can be
discarded, glial CB2Rs may also regulate the AIS.
In order to rule out that ankyrinG reduction due to CB1R
antagonist could be due to CB1Rs expressed by glial cells, we
nucleofected hippocampal neurons with plasmids expressing
the CB1R interference RNA (shCB1) or its corresponding
scrambled RNA (shScr). We used previously validated shRNAs
that were able to suppress ∼50% of CB1R protein and
mRNA expression in P19 cells (Diaz-Alonso et al., 2012).
CB1R reduction in hippocampal neurons was confirmed by
assessing CB1R expression in 3 DIV neurons nucleofected
with shCB1 or shScr plasmids (Figure 6A) using a CB1R
antibody that recognizes the extracellular N-terminal domain.
CB1R signal was detected at the distal region of the axon
only in shScr control neurons, while it was not detectable
in shCB1 expressing neurons, confirming the validity of our
plasmids. Then, we analyzed ankyrinG expression and dendrite
length in nucleofected neurons kept for 5 DIV (Figure 6B).
In 5-DIV shCB1 neurons, ankyrinG signal at the AIS was
almost absent (2.46 ± 0.74% compared to 100 ± 13.73% shScr
neurons, Mann-Whitney Rank test, p < 0.001, Figure 6C).
Analysis of dendrite length in the same neurons showed a
reduction in dendritic length ofmore than 50% in shCB1 neurons
(159.88 ± 13.33 µm compared to 341.55 ± 24.35 µm in shScr
neurons, Mann-Whitney Rank test, p < 0.001, Figure 6D).
In order to confirm these results in neurons with a higher
degree of dendritic development, we analyzed the data in
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FIGURE 5 | Glial type-2 cannabinoid receptors (CB2Rs) modulation of AIS. (A,B) 10-DIV hippocampal neurons treated daily with the CB2R antagonist
AM630 from 7 to 10 days. Neurons were grown in the presence of a glial cell layer until 7 days (co-culture). Then, one group was treated in the presence of glial cells
(A) and the second group was transferred to other plates containing only conditioned medium (B). Neurons were stained with the somatodendritic marker MAP2
(red) and ankyrinG (green). Scale bar = 100 µm. (C,D) Graphs representing normalized ankyrinG fluorescence intensity profile along the AIS in control or
AM630-treated neurons in the presence (C) or absence (D) of glial cells. (E) Graph representing the normalized total ankyrinG fluorescence intensity at the AIS of
neurons represented in (C,D). Data were acquired from three independent experiments (30 neurons/experimental condition in each experiment). Mann-Whitney Rank
test. ∗p < 0.05.
9-DIV nucleofected neurons (Figure 6E). shCB1 neurons
showed a clear reduction of ankyrinG staining all along the
AIS (Figure 6F), and a total ankyrinG fluorescence intensity
30% lower than in shScr control neurons (69.2 ± 5.4% vs.
100 ± 6.24% in shScr neurons, Mann-Whitney Rank test,
p < 0.001, Figure 6G), in line with the results obtained
previously with CB1R antagonists (Figure 3). This reduction was
not associated to any change in position, length or maximum
fluorescence position. Therefore, these experiments demonstrate
that the effects of CB1R antagonists are due to neuronal CB1R
inhibition. Next, we analyzed dendrite length in 76 of these
neurons (36 shScr; 40 shCB1) and, as had been observed for
5-DIV nucleofected neurons (Figure 6D) and 6-DIV neurons
treated with CB1R antagonists (Figure 2B), dendrite length
was significantly reduced. While control shScr 9-DIV neurons
had a mean total dendritic length of 710.31 ± 44.7 µm, mean
dendritic length of shCB1 neurons was only 518.96 ± 35.38
µm (Figure 6H, bar plot on the right, Mann-Whitney Rank
test, p < 0.01). To test a possible relationship between dendrites
and AIS, we performed a cell-to-cell correlation of these two
parameters in both conditions (Figure 6H). Dendritic length
and AnkyrinG intensity were found to be positively correlated
in the whole neuronal population (p < 0.001, n = 76),
but also in neurons of each experimental condition taken
separately (p < 0.005 for 36 shScr neurons and p < 0.01 for
40 shCb1 neurons). Moreover, a positive correlation was also
obtained between ankyrinG fluorescence intensity and dendritic
length in 5-DIV neurons (p < 0.0001, Pearson product moment
test). Altogether these results confirm that functional neuronal
CB1Rs contribute, likely through dendritic growth regulation, to
ankyrinG accumulation at the AIS in hippocampal neurons at
both early and late stages of development. Moreover, our results
also show that CB1R-mediated changes in AIS composition and
dendritic growth are correlated at initial dendritic development
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FIGURE 6 | Early CB1R suppression decreases ankyrinG concentration at the AIS and reduces dendritic length. (A) 3-DIV hippocampal neurons
nucleofected with scrambled interference RNA (shScr) or CB1R interference RNA (shCB1). Nucleofected neurons were identified based on GFP fluorescence.
Surface CB1 receptor expression (red) was identified using a CB1R antibody that recognizes an extracellular epitope at the N-terminal domain. Note that CB1R
staining was performed in living neurons at 37◦C and neurons were rinsed quickly before fixation, generating the observed background. (B) Representative images of
5-DIV hippocampal neurons nucleofected with CB1R interference RNA (shCB1) or scrambled interference RNA (shScr). Neurons were stained with MAP2 antibody
(blue) and ankyrinG antibody (red). Nucleofected neurons were identified based on GFP fluorescence. Insets show the AIS region. Note the strong reduction of
ankyrinG staining and dendritic length in 5 DIV shCB1 neurons compared to shScr neurons. (C,D) Bar plots representing the mean ± SEM of normalized total
(Continued)
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FIGURE 6 | Continued
AnkyrinG fluorescence intensity along the AIS (C) and total dendritic length of
5-DIV nucleofected neurons (D, n = 24, 13 shScr, 11 shCB1).
(E) Representative images of 9-DIV hippocampal neurons nucleofected with
CB1R interference RNA (shCB1) or scrambled interference RNA (shScr). Scale
bar = 100 µm. The right panels show higher-magnification images of the AIS
for the nucleofected neurons represented on the left panels. (F) AnkyrinG
fluorescence intensity profile along the AIS of shScr- or shCB1-nucleofected
neurons. Data were obtained from at least 40 neurons of each condition from
three independent experiments. (G) Normalized ankyrinG total fluorescence
intensity at the AIS for the neurons represented in (B). Mann-Whitney Rank
test ∗∗∗ p < 0.001. (H) Cell-to-cell analysis of the relationship between
dendrite length and ankyrinG total fluorescence intensity at the AIS in 9-DIV
nucleofected neurons. Scatter plot illustrating the significant correlation
between ankyrinG intensity fluorescence (x-axis) and dendrite length (y-axis) of
76 nucleofected neurons (36 shScr, gray dots; 40 shCB1, light red dots).
Regression lines and the r2 and p values for all neurons (black), for shScr
neurons (gray) and shCB1 neurons (red) are indicated on the graph (Pearson
product moment test). Bright colored dots represent the average (± SD) for
the two groups. The bar plots shown on the right and top of the graph
represent the mean (± SEM) for the cells plotted for each group, and
significant statistical differences are represented. Mann-Whitney Rank test.
∗∗∗p < 0.001, ∗∗p < 0.01. a.u., arbitrary units.
stages. Thus, a CB1 basal activity is necessary during very early
neuronal development for AIS development and maturation.
Further studies are necessary to understand which role pre- and
post-synaptic CB1Rs may play on AIS maturation and plasticity
within intact networks.
DISCUSSION
The ECS was initially characterized as a retrograde synaptic
signaling system in the adult brain, where postsynaptically
released eCBs bound to presynaptic CB1 receptors in GABAergic
terminals (Katona et al., 1999; Ohno-Shosaku et al., 2001; Wilson
and Nicoll, 2001). However, the classical view of the ECS in
the CNS has dramatically changed over the last two decades,
and in this new scenario the eCB system has been reported
to regulate functions in many neuronal subtypes, in different
subcellular locations, and to be associated with a plethora of
down-stream modulators (Busquets Garcia et al., 2016; Lu and
Mackie, 2016). Moreover, during CNS development the eCB
system undergoes readjustments at multiple levels, showing the
tremendous complexity of its effects on neuronal physiology
(Katona and Freund, 2012).
In this study, we focused on the role of the eCB system
during different stages of in vitro axonal, dendritic and AIS
development. We show for the first time that neuronal CB1R
basal activity indirectly contributes to AIS proteins accumulation
during AIS initial development through the modulation of early
developmental dendritic growth. Our data demonstrate that
neuronal CB1Rs modulate axonal and dendritic morphology
in very early stages of development. Moreover, our results
demonstrate a correlated influence of these receptors on
dendritic length and ankyrinG density at the AIS. In addition,
we have identified a more modest role for glial CB2R in
AIS modulation. These results suggest that a fine-tuned eCB
signaling early in neuronal development acts as a modulator
and coordinator of neuronal morphology and AIS composition
(Figure 7).
Modulation of Axonal and Dendritic
Development by Cannabinoids
Our results show that CB1R is immunodetected in the distal
part of the axon. However CB1R activity is not essential
for axon establishment or the proper elongation of the axon
at initial developmental stages, although its activation by
2-AG potentiates axonal growth and ramification in cultured
hippocampal neurons. Several groups have suggested that
CB1R antagonism/agonism can either promote or inhibit axon
elongation and/or ramification depending on the agonist or
antagonist used, the time of exposure, the age of culture and
the type of neurons used (Gaffuri et al., 2012). Moreover,
the strength of coupling of CB1Rs to downstream signaling
pathways seems to also depend on the neuronal population
considered: while CB1Rs are expressed at lower densities
in glutamatergic neurons compared to GABAergic neurons,
they are more strongly coupled to G-protein signaling in
the first cell type (Steindel et al., 2013). These glutamatergic
neurons represent 95% of the neurons in our primary cultures
(Benson et al., 1994). Thus, differences between experimental
models may partially explain the heterogeneity of data. In this
study, we clearly demonstrate that an increase in 2-AG levels
(exogenous or endogenous—induced by MAGL inhibition)
potentiates axonal growth of hippocampal neurons in vitro in
a CB1R-dependent manner. The question remains whether the
effect of CB1R on axon elongation and ramification is direct
or indirect. CB1R activation has been shown to induce the
expression of trophic factors, such as BDNF, that promote
axon growth and branching (Danzer et al., 2002; Derkinderen
et al., 2003; Marsicano et al., 2003). Moreover, several studies
showed a crosstalk between tyrosine kinase receptors and the
eCB system in several neuronal subtypes: CB1R can form
complexes and trans-activate TrkB receptors (Berghuis et al.,
2005) or couple activated FGF receptors to an axonal growth
response in cultured neurons (Williams et al., 2003). In addition,
CB1R is also linked to other signaling pathways involved
in neuronal differentiation and axonal growth (Keimpema
et al., 2011; Galve-Roperh et al., 2013), such as the PI3K-
Akt-GSK3 pathway (Ozaita et al., 2007) or JNK (Rueda et al.,
2000).
Regarding dendritic development and unlike what happens
during axonal development, triggering CB1R activation by 2-AG
has no effect on dendritic elongation. However, our results point
to a basal CB1R activity necessary for dendritic development,
suggesting a CB1R differential regulation of axonal and dendritic
development. Although our results show an axonal distribution
of CB1R by immunofluorescence, CB1R may have a transient
expression in dendrites after which somatodendritic endocytosis
may contribute to target the receptor to the axon (Leterrier
et al., 2006; McDonald et al., 2007). This axonal polarization
process due to somatodendritic endocytosis has been described
for other proteins in neurons (Garrido et al., 2001; Sampo
et al., 2003). This differential regulation of axon and dendrites
development by CB1R can be explained by differential basal
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FIGURE 7 | Model of CB1R modulation of neuronal morphology and AIS. Schematic showing the functional implication of CB1R activity at different stages of
neuronal development in vitro. Neuronal developmental stages 1–5 have been defined previously by Dotti et al. (1988). Stage 3 is characterized by axonal
polarization and elongation, while dendritogenesis and AIS development occurs from stages 4–5. In both cases, figures represent the effect of CB1R inhibition or
suppression at stage 1, when neurons are not yet polarized. Left, during initial stages of neuronal polarization and axonal elongation, CB1Rs display low or negligible
activity (red) in the axon. Exogenous or endogenous increase of 2-AG level (through MAGL inhibition, red dots; or exogenous application, green dots) promotes
axonal elongation and branching through CB1R activation (blue). Evidence so far suggests that endogenous 2-AG may come from glial or neuronal cells. Right, at
later stages of neuronal development (stages 4–5), CB1R activity (blue) in the dendrites and/or in the axons terminals and synapses contributes to dendritic and AIS
development. Reducing CB1R activity or expression (red) impedes dendritic growth and reduces ankyrinG levels in the AIS.
activity of the receptor in each domain. CB1Rs are constitutively
active in dendrites due to 2-AG local production, while axonal
CB1Rs are not constitutively active (Ladarre et al., 2015).
Local dendritic 2-AG production may explain why exogenous
addition of 2-AG does not promote dendritic growth, while
CB1R inhibition impairs dendritic elongation. On the other
hand, the fact that axonal CB1Rs have no basal activity may
explain why CB1R antagonists have no effect, and why only
exogenous CB1R activation promotes axonal growth. This
subcellular difference in CB1R activity may lead to differential
inhibition of adenylyl cyclases and differences in cAMP and
cGMP concentrations in both neuronal compartments. In fact,
higher cAMP levels in axons are associated with axon formation
and elongation, while dendritic development correlates with
lower cAMP levels and higher cGMP levels (Shelly et al.,
2010). Thus, the difference of CB1R activity and signaling
between both compartments may explain the opposite results
obtained with 2-AG and CB1R antagonists between axons and
dendrites.
Endocannabinoid System and Axon Initial
Segment Formation and Maturation
Development of neuronal domains follow a well-defined time
course in cultured hippocampal neurons (Dotti et al., 1988),
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where AIS initial formation and maturation take place after
early axonal elongation and coincides with initial dendritic
development. In this study, we demonstrate that functional
neuronal CB1Rs participate in the regulation of AIS proteins
composition, through the modulation of dendritic development.
CB1R inhibition or knockdown reduced ankyrinG expression
at the AIS, while CB1R activation had no significant effect
on ankyrinG levels. Since CB1R location at the AIS has
not been detected so far, we can hypothesize that axonal
or dendritic CB1R activity is responsible for the changes in
ankyrinG density we observed. In our low-density cultures
and during early stages of development, neurons have not yet
developed dendritic spines and neuronal connectivity is very
low, making the hypothesis of a CB1R effect on dendrites
the most plausible hypothesis to explain AIS changes during
these stages. In fact, we demonstrate a significant positive
correlation between dendritic length and ankyrinG levels in
both control neurons expressing CB1R or neurons where CB1R
expression was knocked down using RNA interference. In
other words, our results show that a tonic CB1R activation
would be critical for a proper initial dendrite growth, which
modulate subsequent AIS development and maturation. This
dendritic-AIS correlation only occurs when CB1R activity is
impaired from very early stages of development. Nevertheless,
CB1R inhibition at later stages of development (6 DIV, after
dendrite maturation has started and neuronal connectivity
increases) affects the AIS by reducing ankyrinG density. Thus, at
later stages, we cannot rule out that reduced CB1R presynaptic
activity may also participate in the modulation of AIS when
dendritic development is not impaired by CB1R inhibition.
Previous studies have shown a relationship between axonal and
dendritic growth and ankyrinG density at the AIS. For example,
impaired activity of the tubulin deacetylase HDAC6 reduces
axonal and dendritic growth in early stages of development,
and at the same time reduces AIS protein density (Kim
et al., 2009; Tapia et al., 2010). Also, a recent study from
the Südhof laboratory described a tight relationship between
dendritic size, axonal growth and ankyrinG density at the
AIS in neurons after L1CAM conditional deletion (Patzke
et al., 2016). Moreover, a very recent study demonstrates
that AIS distance to the soma in cortical layer 5 pyramidal
adult neurons inversely correlates with dendritic complexity
(Hamada et al., 2016), supporting the idea that dendritic
morphology and AIS might be regulated in a coordinated
manner in several neuronal types. Taking these studies and
our results into account, change in dendritic morphology
induced by CB1R lack of function is the more plausible
hypothesis to explain AIS changes. However, we cannot rule
out the existence of a direct effect on AIS due to unknown
mechanisms.
These results raise the question of which mechanisms,
and related molecules and receptors, are involved in the
CB1R-mediated modulation of the AIS. CB1R signaling
mechanisms are highly complex and diverse, and these receptors
have many other effectors apart from their canonical targets
(see ‘‘Introduction’’ Section). Somatodendritic CB1Rs play
a key role in short-term regulation of intrinsic excitability
through the activation of GIRK channels (Bacci et al., 2004;
Marinelli et al., 2009) but also by regulating the baseline levels
of the Ih current (hyperpolarization-activated cationic current)
in pyramidal hippocampal neurons (Maroso et al., 2016).
Moreover, presynaptic CB1Rs are widely involved in short and
long-term plasticity events at inhibitory and excitatory synapses
(Chevaleyre et al., 2006; Kano et al., 2009). Thus, secondary
changes in AIS maybe attributed to CB1R mediated changes
in intrinsic excitability and/or in synaptic strength. CB1R may
exert these neuromodulatory effects cooperating with other
receptors, such as glutamate receptors (Varma et al., 2001),
or even modulating the release of neurotransmitters, such as
glutamate (Gerdeman and Lovinger, 2001). For instance, a
crosstalk between purinergic receptors and the ECS has been
proposed. In fact, several groups have recently reported that the
purinergic system may participate in cannabinoid-dependent
synaptic modulation, thus demonstrating the existence of
a crosstalk between these two families of receptors (Kovacs
et al., 2011; Ievglevskyi et al., 2012). Similar to what has been
observed for CB1Rs, purinergic receptors are absent from the
AIS but are expressed in the somatodendritic domain and
axon terminals (del Puerto et al., 2012; Shrivastava et al., 2013;
Pougnet et al., 2014). Moreover, P2X7 receptors modulate
the density of ankyrinG and sodium channels at the AIS
(del Puerto et al., 2015). Whether the crosstalk between
CB1R and P2X7 receptors is involved in AIS modulation
remains elusive, however both are able to modulate G proteins
(Howlett et al., 1998; del Puerto et al., 2012) and signaling
molecules like GSK3 (Ozaita et al., 2007; del Puerto et al.,
2012), which participates in AIS modulation (Tapia et al.,
2013).
Regarding our results showing an astroglial CB2R-dependent
modulation of the AIS, one study in a GFP-CB2R transgenic
mouse has detected the expression of CB2R in microglia cells,
but not in astrocytes or neurons (Schmöle et al., 2015). We
assessed whether microglia cells were present in our glial
cultures by detecting a specific microglial marker, Iba-1, and
found only a few (or none) microglia cells that are unlikely
to explain the observed effect. Nevertheless, it is still possible
that cultured astrocytes express very low levels of CB2Rs,
even though CB2Rs have only been detected in astrocytomas
(Sánchez et al., 2001). Further studies and the development of
tools for CB2R detection will be necessary to investigate the
potential role of CB2R in the regulation of AIS and neuronal
excitability in physiological and pathological conditions. In fact,
CB2Rs have been detected in neurons and glial cells only
in pathological conditions (Viscomi et al., 2009; Choi et al.,
2013).
CONCLUSION
Our results show that cannabinoid receptors play an important
role in coordinating dendritic development and maturation of
the AIS, which may influence future events during neuronal
maturation. While CB1Rs have been thoroughly studied at
presynaptic and postsynaptic sites, our study show that CB1R
modulation of dendritic growth also modulates ankyrinG
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density, and therefore voltage-gated sodium channel density
at the AIS. Further studies regarding cannabinoid receptors
are necessary to understand the role the ECS may have in
the regulation of AIS structure and plasticity, and its relation
with the presynaptic and postsynaptic domains. Furthermore,
understanding AIS modulation in response to brain disorders,
diseases or injury also requires to consider changes in other
neuronal compartments.
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